Eli Lilly CEO Says Drugmaker Won’t Rehash Old Alzheimer’s Data
- Ricks says patients must have confidence in research methods
- Surprising Biogen news offers a glimmer of hope, he says
This article is for subscribers only.
Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
Eli Lilly & Co. Chief Executive Officer David Ricks said the pharmaceutical giant wouldn’t be revisiting a study that found its own promising drug failed to slow the progression of Alzheimer’s. To do so would be to call into question their research methods, Ricks said.